LBI-HTA - Publications - Search - Horizon Scanning in Oncology 39th Prioritisation – 2nd quarter 2019

Groessmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 39th Prioritisation – 2nd quarter 2019 . HSO: 39th Prioritisation.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
132Kb
Abstract

For the 39th prioritisation (April 2019), 10 drugs were filtered out of 507 identified and were sent to prioritisation. Of these, three drugs were ranked as 'highly relevant' by the expert panel, seven as 'relevant' and none as 'not relevant'. For 'highly relevant' drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.

Item Type:DSD: Horizon Scanning in Oncology
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:English
Series Name:HSO: 39th Prioritisation
Deposited on:24 Apr 2019 12:45
Last Modified:24 Apr 2019 12:45

Repository Staff Only: item control page